95 Results

People

  1. Hassoun
    Hassoun
  2. Shah
    Shah
  3. Giralt
    Giralt
  4. Lesokhin
    Lesokhin
  5. Landau
    Landau
  6. Korde
    Korde
  7. Mailankody
    Mailankody
  8. Chung
    Chung
  9. Scordo
    Scordo
  10. Shah
    Shah

Groups

  1. Bone Marrow Transplant (95)
  2. Center for Hematologic Malignancies (95)
  3. Department of Medicine (95)
  4. Hematologic Malignancies, Division of (95)
  5. Myeloma (95)
  6. Survivorship Research (95)
  7. Hematologic Malignancies Research (92)
  8. Sloan Kettering Institute Postdocs (82)
  9. CTCR Scholars (80)
  10. Epidemiology and Biostatistics (70)
  1. "Center for Hematologic Malignancies"
  2. "Myeloma"
  3. "Gunjan Shah"
  4. "Hani Hassoun"
Formats
  1. Meeting Abstract (78)
  2. Journal Article (14)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. Bone Marrow Transplant (95)
  2. Center for Hematologic Malignancies (95)
  3. Department of Medicine (95)
  4. Hematologic Malignancies, Division of (95)
  5. Myeloma (95)
  6. Survivorship Research (95)

More Groups

People
  1. Gunjan Shah (95)
  2. Hani Hassoun (95)
  3. Sergio Giralt (94)
  4. Alexander Lesokhin (92)
  5. Heather Landau (91)
  6. Neha Korde (88)

More People

Years
  1. 2023 (32)
  2. 2022 (22)
  3. 2021 (10)
  4. 2020 (9)
  5. 2019 (8)
  6. 2018 (5)

More Years

Publications
  1. Blood (39)
  2. Clinical Lymphoma, Myeloma and Leukemia (25)
  3. Biology of Blood and Marrow Transplantation (9)
  4. Journal of Clinical Oncology (6)
  5. Leukemia and Lymphoma (3)
  6. American Journal of Hematology (2)

More Publications

Publishers
  1. American Society of Hematology (39)
  2. Elsevier Inc. (36)
  3. American Society of Clinical Oncology (6)
  4. Taylor & Francis Group (3)
  5. American Association for Cancer Research (2)
  6. John Wiley & Sons, Inc. (2)

More Publishers

Results (95)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The complex structural variant chromothripsis can be defined on targeted sequencing panels, allowing direct clinical translation in order to improve multiple myeloma prognostication
    Meeting Abstract

    Maclachlan, K. H.; Ziccheddu, B.; Tan, C.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Diamond, B.; Hassoun, H.; Mailankody, S.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Stem cell utilization in the era of novel therapies for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Nemirovsky, D.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save